Primary tumor resection improves survival of gastrointestinal neuroendocrine carcinoma patients with nonresected liver metastases
- PMID: 36807890
- DOI: 10.1002/jso.27213
Primary tumor resection improves survival of gastrointestinal neuroendocrine carcinoma patients with nonresected liver metastases
Abstract
Background: The role of primary tumor resection (PTR) in the survival of gastrointestinal neuroendocrine carcinoma (GI-NEC) patients with liver metastases only remains poorly defined. Therefore, we investigated the impact of PTR on the survival of GI-NEC patients with nonresected liver metastases.
Methods: GI-NEC patients with a liver-confined metastatic disease diagnosed between 2016 and 2018 were identified in the National Cancer Database. Multiple imputations by chained equations were used to account for missing data, and the inverse probability of treatment weighting (IPTW) method was used to eliminate selection bias. Overall survival (OS) was compared by adjusted Kaplan-Meier curves and log-rank test with IPTW.
Results: A total of 767 GI-NEC patients with nonresected liver metastases were identified. Among all patients, 177 (23.1%) received PTR and had a significantly favorable OS before (median: 43.6 months [interquartile range, IQR, 10.3-64.4] vs. 8.8 months [IQR, 2.1-23.1], p < 0.001 in log-rank test) and after (median: 25.7 months [IQR, 10.0-64.4] vs. 9.3 months [IQR, 2.2-26.4], p < 0.001 in IPTW-adjusted log-rank test) the IPTW adjustment. Additionally, this survival advantage persisted in an adjusted Cox model (IPTW adjusted hazard ratio = 0.431, 95% confidence interval: 0.332-0.560; p < 0.001). The improved survival persisted in subgroups stratified by primary tumor site, tumor grade, and N stage, even in the complete cohort (excluding patients with missing data).
Conclusions: PTR led to improved survival for GI-NEC patients with nonresected liver metastases regardless of primary tumor site, tumor grade, and N stage. However, the decision for PTR should be made on an individualized basis following multidisciplinary evaluation.
Keywords: National Cancer Database; gastrointestinal neuroendocrine carcinoma; liver metastases; primary tumor resection.
© 2023 Wiley Periodicals LLC.
Similar articles
-
Resection of the Primary Gastrointestinal Neuroendocrine Tumor Improves Survival With or Without Liver Treatment.Ann Surg. 2019 Dec;270(6):1131-1137. doi: 10.1097/SLA.0000000000002809. Ann Surg. 2019. PMID: 29746336
-
Resection of the Primary Tumor Improves the Survival of Patients With Stage IV Gastric Neuroendocrine Carcinoma.Front Oncol. 2022 Jul 14;12:930491. doi: 10.3389/fonc.2022.930491. eCollection 2022. Front Oncol. 2022. PMID: 35912176 Free PMC article.
-
Resection of the primary tumor improves the prognosis of gastrointestinal neuroendocrine neoplasms with liver metastases: mutual validation based on SEER database and institutional data.BMC Gastroenterol. 2023 Nov 23;23(1):408. doi: 10.1186/s12876-023-03041-6. BMC Gastroenterol. 2023. PMID: 37993767 Free PMC article.
-
Impact of primary tumor resection and metastasectomy among gastroentero-pancreatic neuroendocrine tumors with liver metastases only on survival.HPB (Oxford). 2024 Jan;26(1):125-136. doi: 10.1016/j.hpb.2023.09.016. Epub 2023 Sep 21. HPB (Oxford). 2024. PMID: 37806829
-
Hepatic surgery for metastases from neuroendocrine tumors.Surg Oncol Clin N Am. 2003 Jan;12(1):231-42. doi: 10.1016/s1055-3207(02)00076-5. Surg Oncol Clin N Am. 2003. PMID: 12735141 Review.
Cited by
-
Global status of research on gastrointestinal cancer patients' quality of life: A bibliometric and visual analysis from 2003 to 2023.Heliyon. 2023 Dec 6;10(1):e23377. doi: 10.1016/j.heliyon.2023.e23377. eCollection 2024 Jan 15. Heliyon. 2023. PMID: 38148818 Free PMC article.
References
REFERENCES
-
- Borga C, Businello G, Murgioni S, et al. Treatment personalization in gastrointestinal neuroendocrine tumors. Curr Treat Options Oncol. 2021;22(4):29.
-
- Dasari A, Mehta K, Byers LA, Sorbye H, Yao JC. Comparative study of lung and extrapulmonary poorly differentiated neuroendocrine carcinomas: a SEER database analysis of 162,983 cases. Cancer. 2018;124(4):807-815.
-
- Zandee WT, de Herder WW. The evolution of neuroendocrine tumor treatment reflected by ENETS guidelines. Neuroendocrinology. 2018;106(4):357-365.
-
- Sorbye H, Welin S, Langer SW, et al. Predictive and prognostic factors for treatment and survival in 305 patients with advanced gastrointestinal neuroendocrine carcinoma (WHO G3): the NORDIC NEC study. Ann Oncol. 2013;24(1):152-160.
-
- Feng T, Lv W, Yuan M, Shi Z, Zhong H, Ling S. Surgical resection of the primary tumor leads to prolonged survival in metastatic pancreatic neuroendocrine carcinoma. World J Surg Oncol. 2019;17(1):54.
MeSH terms
LinkOut - more resources
Full Text Sources
Medical